Background: The CMS recently supported the CDC and USPSTF grade B recommendation, and now covers a single HCV screening test if ordered by a primary care provider (PCP) to screen all persons born 1945-1965 (Birth Cohort) given a 3.25% prevalence rate. Previously published HCV rates of 2.5% in all persons in Washington, DC, and other urban areas, will likely increase with expanded testing.
Methods: In December 2012, we established a HCV testing program in the Primary Care Clinic at MedStar Washington Hospital Center, with CDC grant funding, to enhance testing for HCV infections among the Birth Cohort and not previously aware of their infection, link to care, and provide counseling, treatment and preventative services. Eligibility includes: born 1945-1965, without predetermined risk factors listed in the medical record, and not previously HCV tested or positive. HCV antibody positive (Ab+) patients are linked to care with Infectious Disease or Gastroenterology regardless of RNA status. Results reflect enrollment data from both the original grant and additional an CDC grant for expanded testing.
Results: As of September 23, 2014, 7.8% of the 1875 tested were HCV Ab+, 54% HCV RNA+, and this was no different from the first grant. Mean age of HCV Ab+ was 59.9 + 5.6 years; 53.1% were men, and 76% had public insurance (Medicare or Medicaid); 85% of those tested, and 93% of those HCV Ab+ were black (13% b/AA men, 6% b/AA women). Those HCV Ab+ were more likely to be men (OR 1.9 [CI95 1.1-3.4]) and have public insurance (OR 2.8 [CI95 1.9-4.1]) than HCV Ab -. Unique primary care clinic appointments for those eligible (1st documented visit identified in the EMR) were 4016: 1248(31%) were tested, 974(24%) were missed (not tested but completed appointment), and 1794(45%) either canceled or no-showed.
Conclusions: The HCV Ab+ prevalence rate of 7.8% remained consistent over the two years and is significantly higher than the CDC Birth Cohort rate of 3.25% and the Washignton, DC rate of 2.5%, although the latter reports all ages. Overall screening uptake, however, remains low at 24%. Given these high prevalence rates, new CMS recommendations, and improved therapeutic options available, testing initiatives in Primary Care settings need to be more rigorously upheld, and internal champions are needed to advocate for increased screening to ensure linkage to care and engagement within the HCV care cascade.